Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,075 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
4 Weeks Versus 5 Weeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer: Interim Safety Analysis of a Randomized Phase 3 Trial.
Fonteyne V, Sarrazyn C, Swimberghe M, De Meerleer G, Rammant E, Vanderstraeten B, Vanpachtenbeke F, Lumen N, Decaestecker K, Colman R, Villeirs G, Ost P. Fonteyne V, et al. Among authors: colman r. Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):866-870. doi: 10.1016/j.ijrobp.2017.12.016. Epub 2017 Dec 19. Int J Radiat Oncol Biol Phys. 2018. PMID: 29485064 Clinical Trial.
Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial.
Rammant E, Ost P, Swimberghe M, Vanderstraeten B, Lumen N, Decaestecker K, Bultijnck R, De Meerleer G, Sarrazyn C, Colman R, Fonteyne V. Rammant E, et al. Among authors: colman r. Strahlenther Onkol. 2019 May;195(5):393-401. doi: 10.1007/s00066-018-1395-y. Epub 2018 Nov 7. Strahlenther Onkol. 2019. PMID: 30406289 Clinical Trial. English.
Moderate hypofractionated radiotherapy for prostate cancer: 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial.
Fonteyne V, Berghen C, Van Praet C, Vanderstraeten B, Verbeke S, Villeirs G, Colman R, Vanneste B, Ost P, De Meerleer G, Lumen N. Fonteyne V, et al. Among authors: colman r. Radiother Oncol. 2024 Apr;193:110089. doi: 10.1016/j.radonc.2024.110089. Epub 2024 Jan 24. Radiother Oncol. 2024. PMID: 38278333 Clinical Trial.
1,075 results